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Abstract
Introduction: Prostatic metastasis from a primary bowel adenocarcinoma has been only rarely reported in the
medical literature. The case reported here is rare in the fact that the primary tumor was from a right-sided bowel
adenocarcinoma. It is unusual because initial immunostaining was not fully conclusive, and so a relatively new
method of immunostaining, CDX2, was used to ascertain its histopathology.
Case presentation: We describe the case of a 54-year-old Caucasian man who had a right hemicolectomy for a
primary cecal adenocarcinoma, which was completely excised. Following the procedure, he received adjuvant
chemotherapy. Computed tomography scans showed no evidence of local recurrence or metastatic disease. Then,
five years later, he presented to his general practitioner with urinary symptoms. An abnormal prostate was
palpated on digital rectal examination. Trans-rectal prostatic biopsies were performed, which showed colorectal
metastases within the prostate gland. This was confirmed with CDX2 immunohistochemistry. There was no further
evidence of distant metastases on positron emission tomography-computed tomography scans.
Conclusions: This case demonstrates a rare isolated hematogenous spread to the prostate from a primary cecal
adenocarcinoma, several years after definitive treatment and excision. This highlights the importance of accurate
immunohistochemistry and imaging in planning further management and treatment.
Introduction
Prostatic metastasis from a primary bowel adenocarci-
noma has been only rarely reported in the medical lit-
erature. We describe a case of a rare metastasis from a
right-sided primary bowel adenocarcinoma to the pros-
tate gland. It is unusual because a relatively new method
of immunostaining, CDX2, was used to ascertain its
histopathology.
Case presentation
A 54-year-old Caucasian man was admitted to our hos-
pital with an acute history of abdominal pain and vomit-
ing, and a four-month history of changes in bowel
habits. A computed tomography (CT) scan of his abdo-
men and pelvis confirmed a small bowel obstruction
secondary to a mass lesion at the cecal pole. A few
lymph nodes were identified adjacent to the cecal pole,
measuring approximately 1 cm in size.
On laparotomy, a mobile cecal tumor was found, with
no other evidence of intra-abdominal metastatic disease.
A right hemicolectomy was performed. He made an
uneventful recovery and was discharged one week after
surgery.
Histology results showed a moderately differentiated
mucinous adenocarcinoma (pT4, N2, Mx) Dukes C1,
with an incidental carcinoid tumor in the appendix. Sur-
gical resection margins were clear. Carcinogenic
embryonic antigen (CEA) staining was diffusely positive,
cytokeratin 20 (CK20) staining was focally positive, and
cytokeratin 7 (CK7) staining was negative. A CK7-nega-
tive and CK20-positive profile favors a primary colorec-
tal tumor, although CK20 staining was weakly positive.
He underwent adjuvant chemotherapy as part of the
QUASAR (’Quick and Simple and Reliable’) trial [1]. A
post-operative CT scan at six months demonstrated two
small liver lesions and a small lung lesion. These had
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not changed on repeat scans at three months and 12
months. All further follow-up consultations and investi-
gations showed no evidence of recurrence.
After five years of follow-up, he was referred by his
general practitioner to our urology department with
lower urinary tract symptoms and an abnormal prostate
on digital rectal examination. There was a large, sus-
pected to be malignant, extrinsic pelvic mass that could
not be palpated separately from the prostate. His pros-
tate specific antigen (PSA) level was 1.3 ng/ml (normal
range 0 to 4 ng/ml).
Trans-rectal ultrasound prostate biopsies were taken
and results showed normal background prostatic tissue,
with all cores infiltrated with mucinous adenocarcinoma.
Immunohistochemistry results were positive for CEA
staining but negative for PSA, CK7 and CK20 staining.
The original bowel specimen was again analyzed and
the morphology of the tumor in the bowel specimen
was identical to that in the prostate. Additional staining
was performed, and both the bowel and prostatic speci-
mens tested positive for CDX2 (Figure 1). It was con-
cluded that the prostate biopsies contained mucin-
secreting adenocarcinoma with intestinal differentiation,
as indicated by the presence of CDX2, morphologically
identical to the original primary bowel carcinoma, thus
representing a metastasis of this tumor.
A fused positron emission tomography-computed
tomography (PET-CT) scan was performed to exclude
further distant metastatic disease. This demonstrated
increased uptake in the prostate with central necrosis,
consistent with a metastasis (Figures 2 and 3). There
were no other signs of metastatic disease elsewhere. Our
patient is now being considered for radical pelvic exen-
teration with curative intent. Other treatment modalities
would not offer this.
Discussion
There have only rarely been other reported cases of pro-
static metastasis from primary bowel adenocarcinomas
[2-4]. Other primary malignancies have reportedly metas-
tasized to the prostate. These include malignant mela-
noma, lung, pancreas, stomach, penis and larynx [5].
CDX2 is a monoclonal antibody to the intestinal-epithe-
lia-specific nuclear transcription factor, and is a relatively
new marker for gastrointestinal tumors. It is expressed in
the nuclei of intestinal cells throughout the intestine from
duodenum to rectum [6]. Immunohistochemistry has
demonstrated 60% to 98% CDX2 expression in primary
and secondary colorectal adenocarcinomas [7,8]. CDX2 is
also expressed in tumors from other gastrointestinal sites,
Figure 1 Prostatic core demonstrating mucinous
adenocarcinoma with positive CDX2 staining.
Figure 2 Computed tomography (CT) images demonstrating
the prostate with metastatic invasion.
Figure 3 Fused positron emission tomography-computed
tomography (PET-CT) cross-sectional image demonstrating
prostatic metastasis with central necrosis.
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including the esophagus, stomach, pancreatobiliary, gas-
trointestinal carcinoids and liver. High levels have also
been detected in mucinous ovarian carcinomas and adeno-
carcinomas originating from the urinary bladder [9].
Owens et al. demonstrated 60% positivity for CDX2 in
primary colorectal cancers versus 0% expression in pri-
mary prostate cancers [7].
CDX2’s positive nature in the prostate specimens, as
well as the original bowel specimens from this case,
strongly correlate with a diagnosis of metastatic spread
from the original cecal adenocarcinoma to the prostate.
One would expect CK20 staining to be positive in the
prostatic specimens, but staining on the original bowel
tumor was only weakly positive, which may account for
the metastatic focus showing a negative CK20 profile.
This stresses the importance of advanced immunohisto-
chemical and pathological techniques in differentiating
tumor origin in patients with previous malignancy and
uncommon sites of metastatic disease. This enables
accurate diagnosis and appropriate treatment.
Conclusions
This case demonstrates a rare isolated hematogenous
spread to the prostate from a primary cecal adenocarci-
noma, several years after definitive treatment and
excision.
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